Gynecology

A recap of the top stories from August 2026 in women's health.

Take a look back at some of the top FDA and pipeline news in women's health from August 2026.

ACOG updated guidance now recommends routine bilateral salpingectomy at hysterectomy and other surgeries to prevent ovarian cancer.

Livi was cleared by the FDA on March 24, 2026 as a novel device to support vaginal health.

Jeff Andrews, MD, FRCSC, discusses raising awareness of at-home HPV self-collection and identifying appropriate candidates as the option rolls out in the US.

TMP-SMX was linked to higher UTI treatment failure vs. nitrofurantoin and fosfomycin in postmenopausal women.

“Primary care physicians, who traditionally have referred out for speculum exams, can now offer self-collection during routine appointments or problem visits, preventing missed opportunities for patient preventive care,” said Andrews.

Liz Miracle, PT, MPT, WCS, argues that ACOG Committee Opinion No. 736, which supports non-office postpartum assessment, applies equally to virtual pelvic floor physical therapy.

Liz Miracle, PT, MPT, WCS, discusses a retrospective analysis of 4,662 patients finding comparable pelvic health outcomes across virtual, hybrid, and in-person care.

This review aims to go beyond the basics by exploring advanced interpretations for clinical referral to support ob-gyn providers in translating urinalysis findings into practical care decisions.

The FDA has cleared the Revi Extend, furthering the system's lifespan to 15 years to treat UUI.

Michael A. Reed, MD, MSCP, outlines immediate, practical steps physicians can take to address women's sexual health in their current roles.

BV-positive women had higher STI coinfection rates than BV-negative women in a study from Quest Diagnostics and Hologic, Inc.

Michael A. Reed, MD, MSCP, proposes a “Fourth Pillar” framework to integrate women's sexual health alongside reproduction, disease treatment, and longevity in clinical practice.

Roche's cobas BV/CV assay received FDA clearance as a single-swab test for bacterial vaginosis and candida vaginitis.

Damian Alagia, III, MD, joined Contemporary OB/GYN for a discussion on STIs in women, associated stigma, and structural barriers to testing.

ACOG, SWHR, and WFRC are calling on Congress to invest $20B over 10 years to close the women's health gap.

Kate McLean, MD, describes how newly defined bacterial vaginosis subtypes could validate patient symptoms and inform treatment.

The SELF-GYN1 trial found that at-home transvaginal ultrasonography met diagnostic quality standards in 96.2% of scans and was significantly preferred by participants over in-clinic imaging.

89.6% of women tested with Xpert Xpress MVP received appropriate treatment within 24 hours vs 51.9% with usual care.

Kate McLean, MD, MPH, FACOG, describes how statistical clustering of more than 15,000 BV-diagnosed patients surfaced distinct microbial subtypes without predefined assumptions.

Daré Bioscience has launched Flora Sync LF5, a non-prescription vaginal probiotic capsule containing Limosilactobacillus fermentum LF5.

Kate McLean, MD, MPH, FACOG, describes how metagenomic sequencing and new transmission data are reshaping the understanding of bacterial vaginosis beyond a traditional, oversimplified definition.

A reader-driven look at the 10 most-viewed articles on Contemporary OB/GYN from the first half of 2026, spanning FDA decisions, clinical research, and emerging treatments across menopause, contraception, endometriosis, and pelvic health.

A recap of the top FDA news stories covered by Contemporary OB/GYN in Q2 2026, spanning cervical cancer screening, menopause therapeutics, and antibiotic treatment for urinary tract infections.